Copper-Induced Cell Death in Renal Diseases: Molecular Mechanisms and Therapeutic Implications

Copper dyshomeostasis and the resulting induction of cuproptosis, a novel regulated cell death pathway driven by mitochondrial copper overload, play a critical role in renal pathophysiology. Cuproptosis is characterized by FDX1-mediated copper reduction, irreversible aggregation of lipoylated TCA cycle enzymes, such as dihydrolipoamide S-acetyltransferase, and destabilization of iron‒sulfur cluster proteins, leading to proteotoxic mitochondrial collapse. The kidney's high vulnerability arises from its filtration and metabolic functions. This review consolidates evidence linking cuproptosis to various renal disorders, including acute kidney injury (eg, sepsis-induced, cisplatin-induced, and ischemia-reperfusion injury), diabetic nephropathy through mitochondrial dysfunction and immune dysregulation, and chronic kidney disease involving podocyte damage or context-dependent dysregulation in fibrosis and clear cell renal cell carcinoma. Notably, cuproptosis and ferroptosis interact synergistically through shared mechanisms, where glutathione depletion or iron overload exacerbates both pathways, while mitochondrial dysfunction and lipid peroxidation create a self-perpetuating injury cycle. Emerging diagnostic strategies utilize cuproptosis-related biomarkers for early detection, supported by various prediction models. In therapeutic contexts, copper chelators, transporter modulators, and dual-pathway inhibitors targeting both cuproptosis and ferroptosis mitigate renal damage in preclinical models. Dietary interventions that modulate copper bioavailability also hold promise. However, challenges remain, including identifying renal cell type-specific mechanisms, developing noninvasive biomarkers, optimizing kidney-targeted nanotherapeutics, and preventing iatrogenic copper deficiency. Future research may focus on translational applications and the physiological roles of cuproptosis in renal repair. Targeting cuproptosis offers a promising avenue for innovative diagnostics and treatments in nephrology.

Authors

Institutions

Publication Details

Journal
Drug Design Development and Therapy
Published
2025-12-01
DOI
https://doi.org/10.2147/dddt.s562664
Primary Topic
Ferroptosis and cancer prognosis
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Copper-Induced Cell Death in Renal Diseases: Molecular Mechanisms and Therapeutic Implications

Daoyuan Lv, Yafen Yu
Drug Design Development and Therapy
Ferroptosis and cancer prognosis
article

Copper-Induced Cell Death in Renal Diseases: Molecular Mechanisms and Therapeutic Implications

Daoyuan Lv, Yafen Yu
article en

Abstract

Copper dyshomeostasis and the resulting induction of cuproptosis, a novel regulated cell death pathway driven by mitochondrial copper overload, play a critical role in renal pathophysiology. Cuproptosis is characterized by FDX1-mediated copper reduction, irreversible aggregation of lipoylated TCA cycle enzymes, such as dihydrolipoamide S-acetyltransferase, and destabilization of iron‒sulfur cluster proteins, leading to proteotoxic mitochondrial collapse. The kidney's high vulnerability arises from its filtration and metabolic functions. This review consolidates evidence linking cuproptosis to various renal disorders, including acute kidney injury (eg, sepsis-induced, cisplatin-induced, and ischemia-reperfusion injury), diabetic nephropathy through mitochondrial dysfunction and immune dysregulation, and chronic kidney disease involving podocyte damage or context-dependent dysregulation in fibrosis and clear cell renal cell carcinoma. Notably, cuproptosis and ferroptosis interact synergistically through shared mechanisms, where glutathione depletion or iron overload exacerbates both pathways, while mitochondrial dysfunction and lipid peroxidation create a self-perpetuating injury cycle. Emerging diagnostic strategies utilize cuproptosis-related biomarkers for early detection, supported by various prediction models. In therapeutic contexts, copper chelators, transporter modulators, and dual-pathway inhibitors targeting both cuproptosis and ferroptosis mitigate renal damage in preclinical models. Dietary interventions that modulate copper bioavailability also hold promise. However, challenges remain, including identifying renal cell type-specific mechanisms, developing noninvasive biomarkers, optimizing kidney-targeted nanotherapeutics, and preventing iatrogenic copper deficiency. Future research may focus on translational applications and the physiological roles of cuproptosis in renal repair. Targeting cuproptosis offers a promising avenue for innovative diagnostics and treatments in nephrology.

Drug Design Development and TherapyVol. Volume 19
Jiangnan University (CN), Wuxi Fourth People's Hospital (CN)
Jiangnan University
Openalex Percentile: Top 27%
Ferroptosis and cancer prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.